Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06851065 · ClinicalTrials.gov registry record
A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 418
- Enrollment target
NCT06851065 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 418 participants.
The verdict
NCT06851065 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 418 participants
- Enrollment target
Study Summary
The purpose of this study is to understand real-world effectiveness of luspatercept treatment among erythropoiesis-stimulating agents -naïve patients with lower-risk- myelodysplastic syndromes in the United States
Interventions
- DRUG Luspatercept
- DRUG Erythropoiesis-stimulating agents
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2024-08-22 |
| Est. Completion | 2025-03-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06851065
The ClinicalTrials.gov registry entry for NCT06851065 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 418 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Luspatercept is the first listed.
NCT06851065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06851065 about?
NCT06851065 is a clinical study titled "A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States". The purpose of this study is to understand real-world effectiveness of luspatercept treatment among erythropoiesis-stimulating agents -naïve patients with lower-risk- myelodysplastic syndromes in the United States
What is the current status of trial NCT06851065?
This trial is currently completed. The enrollment target is 418 participants. The study started on 2024-08-22. Estimated completion is 2025-03-10.
What interventions are being tested in trial NCT06851065?
The interventions under investigation include: Luspatercept (DRUG), Erythropoiesis-stimulating agents (DRUG).
Who is sponsoring clinical trial NCT06851065?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.